| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 19, 2025The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire
-
Mar 24, 2022
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:...
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Sep 22, 2021Medtronic Will Move to Request Litigation Proceedings Resume
Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed an additional...
-
Sep 13, 2021Medtronic Receives Affirmation of Three Additional Sacral Neuromodulation Patents
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral...